Background
Methods
Patients
Variable | Number | Percentage(%) |
---|---|---|
Total | 31 | 100 |
Age (years) | ||
≤ 55 | 16 | 51.7 |
> 55 | 15 | 48.4 |
Gender | ||
Male | 25 | 80.6 |
Female | 6 | 19.4 |
Smoking | ||
Non-smoker | 8 | 25.8 |
Smoker | 23 | 74.2 |
Histology | ||
Adenocarcinoma | 11 | 35.5 |
Non-adenocarcinoma | 20 | 64.5 |
Histologic grading | ||
Poorly | 16 | 51.6 |
Moderate and well | 15 | 48.4 |
Venous invasion | ||
Negative | 23 | 74.2 |
Positive | 8 | 25.8 |
Pathological stage | ||
I/II | 17 | 54.8 |
III | 14 | 45.2 |
IHC and quantification of CMTM1_v17 positive tumor cells
Statistical analysis
Results
CMTM1_v17 variation in the NSCLC cancers before and after NAC
Variable | Pre-NAC | Post-NAC | ||||
---|---|---|---|---|---|---|
CMTM1_v17 expression no. (%) |
P value | CMTM1_v17 expression no. (%) |
P value | |||
High | Low | High | Low | |||
Age | 0.200 | 0.552 | ||||
≤ 55 | 7(43.8) | 9(56.3) | 7(43.8) | 9(56.2) | ||
> 55 | 10(66.7) | 5(33.3) | 5(33.3) | 10(66.7) | ||
Gender | 0.763 | 0.791 | ||||
Male | 10(40.0) | 15(60.0) | 14(56.0) | 11(44.0) | ||
Female | 2(33.3) | 4(66.7) | 3(50.0) | 3(50.0) | ||
Smoking history | 0.935 | 0.75 | ||||
Non-smoker | 3(37.5) | 5(62.5) | 4(50.0) | 4(50.0) | ||
Smoker | 9(39.1) | 14(60.9) | 13(56.5) | 10(43.5) | ||
Histology | 0.332 | 0.981 | ||||
Adenocarcinoma | 3(27.3) | 8(72.7) | 6(54.5) | 5(45.5) | ||
Non-adenocarcinoma | 9(45.0) | 11(55.0) | 11(55.0) | 9(45.0) | ||
Histologic grading | 0.379 | 0.576 | ||||
Poorly | 5(31.3) | 11(68.7) | 8(50.0) | 8(50.0) | ||
Moderate and well | 7(46.7) | 8(53.3) | 9(60.0) | 6(40.0) | ||
Venous invasion | 0.355 | 0.75 | ||||
Negative | 10(43.5) | 13(56.5) | 13(56.5) | 10(43.5) | ||
Positive | 2(25.0) | 6(75.0) | 4(50.0) | 4(50.0) | ||
Pathological stage | 0.756 | 0.092 | ||||
I/II | 7(41.2) | 10(58.8) | 7(41.2) | 10(58.8) | ||
III | 5(35.7) | 9(64.3) | 10(71.4) | 4(28.6) |
Variables | OS | DFS | ||||
---|---|---|---|---|---|---|
HR | 95%CI |
P value | HR | 95%CI |
P value | |
Age | ||||||
≤ 55 vs > 55 | 0.3624 | 0.1117–1.175 | 0.0908 | 0.3255 | 0.1182–0.8964 |
0.0299
|
Gender | ||||||
Male vs female | 0.7042 | 0.1642–3.020 | 0.6368 | 0.4944 | 0.1269–1.927 | 0.3101 |
Smoking | ||||||
Non-smoker vs smoker | 1.698 | 0.4399–6.552 | 0.4423 | 1.672 | 0.5113–5.469 | 0.395 |
Histology | ||||||
AD vs non-AD | 0.9252 | 0.2659–3.219 | 0.9027 | 0.4909 | 0.1660–1.452 | 0.1985 |
Histologic grading | ||||||
Poorly Moderate and well | 2.005 | 0.6213–6.473 | 0.2445 | 2.079 | 0.7724–5.595 | 0.1474 |
Venous Invasion | ||||||
Negative vs positive | 1.352 | 0.3956–4.619 | 0.6306 | 1.237 | 0.4191–3.653 | 0.6999 |
Pathological stage | ||||||
I/II vs III | 0.3045 | 0.09458–0.9802 |
0.0462
| 0.3044 | 0.1083–0.8553 |
0.024
|
Pre-NAC CMTM1_v17 | ||||||
Low vs high | 0.3753 | 0.09230-1.526 | 0.1708 | 1.002 | 0.3533–2.842 | 0.9971 |
Post-NAC CMTM1_v17 | ||||||
High vs low | 0.1587 | 0.04462–0.5647 |
0.0045
| 0.3099 | 0.1149–0.8360 |
0.0207
|
Variable | OS | DFS | ||||
---|---|---|---|---|---|---|
HR | 95%CI |
p value | HR | 95%CI |
p value | |
Post-NAC CMTM1_v17 | ||||||
Low vs high | 0.074 | 0.008–0.670 |
0.021
| 0.455 | 0.136–1.517 | 0.12 |
Pathological stage | ||||||
I/II vs III | 0.295 | 0.082–1.049 | 0.059 | 0.319 | 0.107–0.951 |
0.04
|
Age | ||||||
≤ 55 vs > 55 | 0.291 | 0.923–0.915 |
0.035
|
CMTM1_v17 expression level was related to chemoresistance and prognosis after NAC
Variable | Overall | Original patients group | Added patients group |
P value |
---|---|---|---|---|
no. (%) | no. (%) | no. (%) | ||
Total | 78(100%) | 31(39.7%) | 47(60.3%) | |
Age | 0.246 | |||
≤ 55 | 32(41.1%) | 16(50.0%) | 16(50.0%) | |
> 55 | 46(58.9%) | 15(32.6%) | 31(67.4%) | |
Gender | 0.793 | |||
Male | 64(82.1%) | 25(39.1%) | 39(60.9%) | |
Female | 14(17.8%) | 6(42.9%) | 8(57.1%) | |
Smoking history | 0.978 | |||
Non-smoker | 20(25.6%) | 8(40.0%) | 12(60.0%) | |
Smoker | 58(74.4%) | 23(39.7%) | 35(60.3%) | |
Histology | 0.661 | |||
Adenocarcinoma | 30(38.5%) | 11(36.7%) | 19(63.3%) | |
Non-adenocarcinoma | 48(61.5%) | 20(41.7%) | 28(58.3%) | |
Histologic grading | 0.549 | |||
Poorly | 37(47.4%) | 16(43.2%) | 21(56.8%) | |
Moderate and well | 41(52.6%) | 15(36.6%) | 26(63.4%) | |
Venous invasion | 0.347 | |||
Negative | 62(79.5%) | 23(37.1%) | 39(62.9%) | |
Positive | 16(20.5%) | 8(50.0%) | 8(50.0%) | |
Pathological stage | 0.744 | |||
I/II | 41(52.6%) | 17(41.5%) | 24(58.5%) | |
III | 37(47.4%) | 14(37.8%) | 23(62.2%) |
Variable | CMTM1_v17 expression no. (%) |
P value | |
---|---|---|---|
High | Low | ||
Age | 0.315 | ||
≤ 55 | 13(40.6) | 19(59.4) | |
> 55 | 22(47.8) | 24(52.2) | |
Gender | 0.308 | ||
Male | 27(42.2) | 37(57.8) | |
Female | 8(57.1) | 6(42.9) | |
Smoking history | 0.593 | ||
Non-smoker | 10(50.0) | 10(50.0) | |
Smoker | 25(43.1) | 33(56.9) | |
Histology | 0.352 | ||
Adenocarcinoma | 13(43.3) | 17(56.7) | |
Non-adenocarcinoma | 22(45.8) | 26(54.2) | |
Histologic grading | 0.465 | ||
Poorly | 15(40.5) | 22(59.5) | |
Moderate and well | 20(48.8) | 21(51.2) | |
Venous invasion | 0.506 | ||
Negative | 29(46.8) | 33(53.2) | |
Positive | 6(37.5) | 10(62.5) | |
Pathological stage | 0.856 | ||
I/II | 18(43.9) | 23(56.1) | |
III | 17(45.9) | 20(54.1) |
Variables | OS | DFS | ||
---|---|---|---|---|
HR(95% CI) |
P value | HR(95% CI) |
P value | |
Age | 0.7963(0.3753–1.689) | 0.5528 | 0.6167(0.3178–1.197) | 0.1531 |
Gender | 0.5719(0.2129–1.536) | 0.2678 | 0.3019(0.1163–0.7836) |
0.0138
|
Smoking history | 1.648(0.7097–3.827) | 0.2452 | 2.134(0.976–4.663) | 0.0575 |
Histology | 0.4711(0.2217–1.001) | 0.0503 | 0.351(0.1761–0.6996) |
0.0029
|
Histologic grading | 1.425(0.6849–2.964) | 0.3435 | 1.714(0.8874–3.312) | 0.1086 |
Venous invasion | 0.6148(0.2552–1.482) | 0.2784 | 0.7369(0.3251–1.670) | 0.4645 |
Pathological stage | 0.3958(0.1894–0.8274) |
0.0137
| 0.3351(0.1717–0.6540) |
0.0014
|
CMTM1_v17 expression | 0.3095(0.1442–0.6643) |
0.0026
| 0.3655(0.1871–0.7142) |
0.0032
|
Variable | OS | DFS | ||||
---|---|---|---|---|---|---|
HR | 95%CI |
P value | HR | 95%CI |
P value | |
CMTM1_v17 | ||||||
High vs low | 3.642 | 1.594–8.324 |
0.002
| 3.094 | 1.507–6.350 |
0.002
|
Pathological stage | ||||||
III vs I/II | 2.862 | 1.316–6.224 |
0.008
| 2.704 | 1.315–5.560 |
0.007
|
Gender | ||||||
Male vs female | 1.026 | 0.399–2.636 | 0.958 | |||
Histology | ||||||
Adenocarcinoma vs non-Adenocarcinoma | 2.038 | 0.879–4.727 | 0.097 |